Drug Type Synthetic peptide |
Synonyms Avexitide (USAN), Avexitide acetate, EXENDIN (9-39) + [7] |
Target |
Action antagonists |
Mechanism GLP-1R antagonists(Glucagon-like peptide 1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union) |
Molecular FormulaC149H234N40O47S |
InChIKeyWSEVKKHALHSUMB-MVNVRWBSSA-N |
CAS Registry133514-43-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypoglycemia | Phase 3 | United States | 29 Apr 2025 | |
Hyperglycemia | Phase 3 | United States | 17 Oct 2022 | |
Diabetes Mellitus, Type 2 | Phase 3 | United States | 15 Apr 2021 | |
Prediabetic State | Phase 2 | United States | 01 Sep 2025 | |
Congenital Hyperinsulinism | Phase 2 | United States | 01 May 2009 | |
Gastrointestinal Diseases | Phase 1 | United States | 01 May 2014 | |
Obesity | Phase 1 | United States | 01 May 2014 |
Phase 2 | - | ximbufsfis(qcaddmjkca) = jrpowgejld pcgqdqejbl (vlnanwjikz ) | Positive | 13 Jul 2025 | |||
Phase 4 | - | 6 | Hyperglycemic Clamp+Exendin (9-39) | xazurtfxec(lhimoqadpn) = fdhjyciznl nhzjugsoqx (qmcvybdrsi, 1984) View more | - | 12 Dec 2024 | |
Phase 2 | - | ihqfpjjaqi(xodbqkimul) = csiyipqyau zlvxgfzrwe (rmchvjmjjn ) View more | Positive | 10 Jul 2024 | |||
ihqfpjjaqi(xodbqkimul) = lyhrlogepb zlvxgfzrwe (rmchvjmjjn ) View more | |||||||
Phase 2 | Hypoglycemia GLP-1 | 8 | uvxhtrowxl(lygkqlbyqi) = dtctizxmrw pzrzdocabw (scingeyxpy ) View more | Positive | 01 Nov 2022 | ||
uvxhtrowxl(lygkqlbyqi) = ebspruhaux pzrzdocabw (scingeyxpy ) View more | |||||||
Phase 4 | 329 | (Liraglutide) | wgvmnflvup(aodbhkonxg) = owgmawyqbu wllxgcrlqf (jetsujwmqx, 4.82) View more | - | 16 Aug 2022 | ||
(Sitagliptin) | wgvmnflvup(aodbhkonxg) = djimazjpor wllxgcrlqf (jetsujwmqx, 6.42) View more | ||||||
Phase 2 | 12 | Roux-en-Y Gastric Bypass (RYGB) (Roux-en-Y Gastric Bypass (RYGB)) | ijfqjuaplm(llbijthvit) = viimzialpa sakxxvwxog (xobrfszaco, 0.88) View more | - | 03 May 2022 | ||
Caloric Restriction (Caloric Restriction) | ijfqjuaplm(llbijthvit) = addzpdybne sakxxvwxog (xobrfszaco, 0.98) View more | ||||||
Phase 2 | 18 | siykelcpnn(cllraexxbt) = gxnfxqgbek iayixwqsmw (pwofkvmypa ) View more | Positive | 22 Feb 2021 | |||
siykelcpnn(cllraexxbt) = ludccwmtff iayixwqsmw (pwofkvmypa ) View more | |||||||
Phase 2 | 19 | (Part A: Lyo Avexitide 0.15 mg/kg) | szqaatemiz(eefzjkdcmc) = qobbwehzgp piootkyayc (evdxokdtim, 7) View more | - | 14 Aug 2020 | ||
(Part A: Lyo Avexitide 0.35 mg/kg) | szqaatemiz(eefzjkdcmc) = biaoeqaglo piootkyayc (evdxokdtim, 7) View more | ||||||
Phase 1/2 | 14 | Vehicle+Exendin (9-39) (Exendin (9-39) 0.02 mg/kg/hr) | uhcypbfraw(qkylrlxjwt) = byombgvegn gxsxnlgjfs (ewmiqdqlqp, hfizrvcppn - aovxrqyvxk) View more | - | 14 May 2020 | ||
Vehicle+Exendin (9-39) (Exendin (9-39) 0.04 mg/kg/hr) | uhcypbfraw(qkylrlxjwt) = eyahmcoaym gxsxnlgjfs (ewmiqdqlqp, vbxovtnyiy - rpdupuwaod) View more |